Home/HEPHAISTOS-Pharma/David Sourdive

DS

David Sourdive

Chairman of the Board

HEPHAISTOS-Pharma

Roles

Chairman of the BoardatHEPHAISTOS-Pharma

EVP, Technical OperationsatCellectis

Therapeutic Areas

HEPHAISTOS-Pharma Pipeline

Drug	Indication	Phase
HEPHA-440	Solid Tumors (e.g., Osteosarcoma)	Preclinical
HEPHA-440 + aPD-1	Solid tumors in combination with checkpoint inhibitor	Preclinical

Leadership Team at HEPHAISTOS-Pharma

Dr. Martine Caroff

Chief Scientific Officer, Co-Founder

Pr. Charles Dumontet

Deputy Director, Co-Founder

Frederic Caroff

Chief Executive Officer

View full HEPHAISTOS-Pharma profile